Spectral AI (MDAI) Q4 2025 earnings review
Regulatory Milestones Achieved, But a Revenue Trough Looms
Spectral AI successfully submitted its critical De Novo 510(k) application for the DeepView System in 2025 and secured a massive $31.7M additional BARDA funding package in March 2026. However, the financials reflect a company in a pre-commercial transition. With the heavy R&D phase of the initial BARDA contract winding down, revenue has been steadily decelerating, dropping to $3.8M in Q4. While headline net income was positive in Q4 due to non-cash warrant adjustments, actual operating losses worsened. Management projects 2026 as a waiting period for FDA clearance, guiding for further revenue contraction to $18.5M.
🐂 Bull Case
The $31.7M additional BARDA funding announced in March 2026 is non-dilutive and augments the existing $54.9M commitment. Combined with $15.4M in cash at year-end, the company has a strong runway to reach commercialization.
The company has crossed its biggest operational hurdle by submitting the DeepView application to the FDA. The pivotal trial data showed significant outperformance vs. clinical judgment, de-risking the eventual H1 2026 clearance target.
🐻 Bear Case
2026 revenue guidance of $18.5M implies a 6% YoY contraction. Until FDA clearance unlocks the U.S. market, the company is 100% reliant on winding-down government R&D contracts.
Despite positive headline earnings in Q4, operating losses more than doubled YoY to $2.5M. The core cash-burn will likely continue until commercial sales begin.
⚖️ Verdict: ⚪
Neutral. The company is successfully executing its regulatory and funding roadmap. However, investors face a fundamental waiting game in 2026 as revenue decelerates ahead of anticipated commercial launch in 2027.
Key Themes
BARDA Doubles Down with $31.7M Injection
In a major post-quarter development, Spectral AI secured an additional $31.7M from BARDA to accelerate DeepView feature enhancements, adding to the $54.9M already committed. This non-dilutive capital is a massive vote of confidence from their anchor partner and provides essential runway as the company awaits FDA clearance.
FDA De Novo Submission Anchors the Bull Thesis
The submission of the DeepView System De Novo 510(k) application is complete. Management previously noted that the supporting validation study involved 164 patients and demonstrated that the AI significantly outperformed the clinical judgment of burn physicians. This sets up H1 2026 as the ultimate binary catalyst for the stock.
DeepView SnapShot M Platform Expansion
Beyond the core cart-based system, the company is developing the SnapShot M—a ruggedized handheld device for military and emergency use. Backed by DoD/MTEC funding, this specific technology iteration utilizes a simpler 510(k) pathway and expands the addressable market beyond specialized burn centers.
The 2026 Revenue Trough
Management's 2026 guidance confirms a transition year. Revenue will be derived almost entirely from the BARDA contract, which is decelerating as the base R&D phase concludes. With zero material commercial sales modeled for 2026, the company lacks near-term topline growth drivers.
Headline Net Income Masks Operating Deterioration
The company reported Q4 2025 net income of $0.6M, a dramatic reversal from a $7.7M loss a year ago. However, this contradicts the underlying operating reality: the profit was entirely driven by a $4.0M non-cash gain from a change in warrant liability fair value. Actual operating losses expanded from $1.1M in 24Q4 to $2.5M in 25Q4.
Macro: Government Operations Impacting Timelines
Because Spectral AI is entirely dependent on a single government agency (BARDA) for revenue and the FDA for its commercial future, macro-political dysfunction is a direct headwind. Prior quarters explicitly highlighted how US government shutdowns slowed interactions with the FDA and delayed BARDA-related work and revenue recognition.
Other KPIs
Stable to improving. G&A expenses fell from $19.9M in FY24, reflecting management's focus on operational efficiencies and reduced third-party accounting/legal spending. Cost control is vital during this pre-commercial phase.
Stable. Margins remained consistent YoY (vs 44.9% in FY24). However, Q4 specifically saw a dip to 39.8%, driven by a lower percentage of reimbursed direct labor as the BARDA contract composition shifted.
Guidance
Decelerating. This implies a ~6% YoY decline from FY25's $19.7M. The forecast reflects the continued, but smaller, development work under the BARDA PBS contract. It explicitly excludes any material contributions from commercial sales of the DeepView System, reinforcing 2026 as a pure waiting period for FDA clearance.
Key Questions
BARDA $31.7M Award Recognition
How will the newly announced $31.7M BARDA funding be recognized over time, and does it present an upside to the current $18.5M revenue guidance for 2026?
Commercial Rollout Readiness
With the FDA submission filed, what specific investments are being made in 2026 to prepare a salesforce and secure reimbursement codes for a 2027 commercial launch?
Spectral IP Spin-off Status
Previous guidance suggested the Spectral IP spin-off was targeted to close in early 2026. What is the current regulatory status with the SEC, and is that timeline still intact?